Yongsheng Zhao

Dr. Yongsheng Zhao


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DCDong Chen
Dong Chen
YTYawen Tan
Yawen Tan
ZLZhichao Li
Zhichao Li
WLWujiao Li
Wujiao Li
LYLei Yu
Lei Yu
YZYongsheng Zhao
Yongsheng Zhao
Context: Papillary thyroid cancer (PTC) has been one of the most frequent endocrine malignancies around the world. Although most PTC patients have a favorable prognosis, a subgroup of patients die, especially when disease recurrence occurs. There is a pressing need for clinically relevant preclinical thyroid cancer models for personalized therapy because of the lack of in vitro models that faithfully represent the biology of the parental tumors. Objective: To understand thyroid cancer and translate this knowledge to clinical applications, patient-derived PTC organoids as a promising new preclinical model were established. Methods: Surgically resected PTC primary tissues were dissociated and processed for organoid derivation. Tumor organoids were subsequently subjected to histological characterization, DNA sequencing, drug screen, and cell proliferation assay, respectively. Results: We describe a 3-dimensional culture system for the long-term expansion of patient-derived PTC organoid lines. Notably, PTC organoids preserve the histopathological profiles and genomic heterogeneity of the originating tumors. Drug sensitivity assays of PTC organoids demonstrate patient-specific drug responses, and large correlations with the respective mutational profiles. Estradiol was shown to promote cell proliferation of PTC organoids in the presence of estrogen receptor α (ERα), regardless of the expression of ERβ and G protein–coupled ER. Conclusion: These data suggest that these newly developed PTC-derived organoids may be an excellent preclinical model for studying clinical response to anticancer drugs in a personalized way, as well as provide a potential strategy to develop prevention and treatment options for thyroid cancer with ERα-specific antagonists.
1

9 January 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
DCDong Chen
Dong Chen
XSXi Su
Xi Su
LZLizhang Zhu
Lizhang Zhu
HJHao Jia
Hao Jia
BHBin Han
Bin Han
YZYongsheng Zhao
Yongsheng Zhao
Backgrounds: Papillary thyroid cancer (PTC), which is often driven by acquired somatic mutations in BRAF genes, is the most common pathologic type of thyroid cancer. PTC has an excellent prognosis after treatment with conventional therapies such as surgical resection, thyroid hormone therapy and adjuvant radioactive iodine therapy. Unfortunately, about 20% of patients develop regional recurrence or distant metastasis, making targeted therapeutics an important treatment option. Current in vitro PTC models are limited in representing the cellular and mutational characteristics of parental tumors. A clinically relevant tool that predicts the efficacy of therapy for individuals is urgently needed. Methods: Surgically removed PTC tissue samples were dissociated, plated into Matrigel, and cultured to generate organoids. PTC organoids were subsequently subjected to histological analysis, DNA sequencing, and drug sensitivity assays, respectively. Results: We established 9 patient-derived PTC organoid models, 5 of which harbor BRAFV600E mutation. These organoids have been cultured stably for more than 3 months and closely recapitulated the histological architectures as well as mutational landscapes of the respective primary tumors. Drug sensitivity assays of PTC organoid cultures demonstrated the intra- and inter-patient specific drug responses. BRAFV600E inhibitors, vemurafenib and dabrafenib monotherapy was mildly effective in treating BRAFV600E-mutant PTC organoids. Nevertheless, BRAF inhibitors in combination with MEK inhibitors, RTK inhibitors, or chemotherapeutic agents demonstrated improved efficacy compared to BRAF inhibition alone. Conclusions: These data indicate that patient-derived PTC organoids may be a powerful research tool to investigate tumor biology and drug responsiveness, thus being useful to validate or discover targeted drug combinations.

1 December 2022 in Nano TransMed
Verified
Journal Article
Open access
PDF file
SWShumin Wang
Shumin Wang
YYYajie Yang
Yajie Yang
SLShenhua Li
Shenhua Li
HCHaibo Chen
Haibo Chen
YZYongsheng Zhao
Yongsheng Zhao
JMJing Mu
Jing Mu
Macrophages are important members of the innate immune system that can be reversibly polarized by different microenvironment signals. Exosomes secreted from cells are lipid bilayer membrane vesicles carrying versatile biomolecules, which displays unique properties and biological functions. Recent studies have shown that macrophage derived exosomes as an extracellular vehicle can deliver diverse cargoes including small molecules, nanoparticles, and biological macromolecules to recipient cells, and thus affect the progression of cancers and other diseases. Moreover, exosomes secreted by different phenotypes of macrophages provide different therapeutic options. Thus, in this review, we summarized recent progress in the macrophage derived exosomes as carriers for delivering different types of cargos. Then the engineering principles and their applications are elaborated. In the end, challenges and prospects of macrophage derived exosomes for drug delivery and disease treatment are also discussed.

13 March 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
HYHao Yang
Hao Yang
QLQingzhuang Liang
Qingzhuang Liang
JZJian Zhang
Jian Zhang
JLJinkun Liu
Jinkun Liu
HWHao Wei
Hao Wei
YZYongsheng Zhao
Yongsheng Zhao
Papillary thyroid cancer (PTC) is a common malignancy of the endocrine system, and its morbidity and mortality are increasing year by year. Traditional two-dimensional culture of cell lines lacks tissue structure and is difficult to reflect the heterogeneity of tumors. The construction of mouse models is inefficient and time-consuming, which is difficult to be applied to individualized treatment on a large scale. Clinically relevant models that recapitulate the biology of their corresponding parental tumors are urgently needed. Based on clinical specimens of PTC, we have successfully established patient-derived organoids by exploring and optimizing the organoid culture system. These organoids have been cultured stably for more than 5 passages and successfully cryopreserved and retried. Histopathological and genome analysis revealed a high consistency of the histological architectures as well as mutational landscapes between the matched tumors and organoids. Here, we present a fully detailed method to derive PTC organoids from clinical specimens. Using this approach, we have developed PTC organoid lines from thyroid cancer samples with a success rate of 77.6% (38/49) until now.

16 October 2023 in Environmental Science: Nano
Verified
Journal Article
Closed access
PDF file
HLHan Li
Han Li
HSHaixia Sun
Haixia Sun
YLYuyu Liu
Yuyu Liu
BYBinghan Yuan
Binghan Yuan
JHJingyuan Hu
Jingyuan Hu
YZYongsheng Zhao
Yongsheng Zhao
Poly(N-isopropylacrylamide) (PNIPAM) is currently the most studied thermosensitive hydrogel. Due to its low critical transition temperature, which is close to human body temperature, it is widely used in the biomedical field. The temperature-sensitive embolic agent based on PNIPAM nanogel utilizes the sol–gel transition characteristics of PNIPAM at different temperatures to solve the contradiction between the fluidity and embolic performance of traditional embolic agents. However, research on the toxicology and safety of PNIPAM-based biomedical materials has not been widely explored. In this study, for the first time, an embolic agent composed of PNIPAM thermosensitive nanogels was taken as the object of research, to explore systematically the potential toxicology risks. We achieved specific detection of PNIPAM nanogels by fluorescent labeling. On this basis, pharmacokinetic, safety, and effectiveness studies were carried out in different animal and in vitro models, and organs in which free nanogels might accumulate when a large number of nanogels enter the blood circulation were analyzed. The results show that PNIPAM-based nanogels have good biocompatibility. This study aims to provide a relevant toxicology research program for PNIPAM-based nanogels and other medical products that may contain nanomaterials, and promote the clinical application of this biomedical material, which has great potential.

23 December 2022 in Nanoscale
Verified
Journal Article
Closed access
PDF file
WXWenjing Xie
Wenjing Xie
HLHan Li
Han Li
HYHouqiang Yu
Houqiang Yu
HZHongfu Zhou
Hongfu Zhou
AGAnran Guo
Anran Guo
LLLi Ling
Li Ling
Iodized oil has an excellent X-ray imaging effect, but it shows poor embolization performance. When used as an embolic agent, it is easily washed off by the blood flow and eliminated from the body. Therefore, it is essential to use iodized oil in combination with solid embolic agents such as gelatin sponge or to perform multiple embolization procedures to achieve the therapeutic effect. In the present study, a poly(N-isopropyl acrylamide)-co-acrylic acid (PNCAA) temperature-sensitive nanogel was synthesized by emulsion polymerization; the nanogel was then emulsified with iodized oil to prepare a thermosensitive iodized oil Pickering gel emulsion (TIPE). The oil–water (O/W) ratio of an O/W emulsion system can reach 4 : 6. When injected into the body, TIPE transforms into a nonflowing coagulated state at physiological temperature; the iodized oil is locked in the emulsion structure, thereby achieving local embolization and continuous imaging effects, which not only retain the X-ray imaging effect of the iodized oil but also improve its embolization effect. Subsequently, we further evaluated renal artery embolization in a normal rabbit renal artery model, and the results showed that TIPE shows a long-term conformal embolization performance and excellent long-term X-ray imaging ability.